Stephen Rozakis is a Senior Investment Analyst at Curi, where the individual began in May 2023, following a role as an MBA Investment Analyst Intern. Previously, significant experience includes working at Novartis Gene Therapies from September 2019 to July 2022 as a Scientist III in Technical Research and Development and as a Bioprocess Engineer focused on Upstream/Cell Expansion. Before that, Stephen was a Process Development Scientist at LigaTrap™ Technologies, LLC from 2016 to 2019. Academic qualifications include an MBA from UNC Kenan-Flagler Business School expected in 2024, a Master of Science in Biomanufacturing from North Carolina State University obtained in 2018, and a Bachelor of Science in Molecular and Structural Biochemistry from North Carolina State University completed in 2016.
This person is not in the org chart
This person is not in any teams
This person is not in any offices